Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Assistance publique - Hôpitaux de Paris. Nord - Université Paris Cité is embarking on a process of continuous evaluation and quality improvement of its placement policy, by transposing the 'patient tracer' method to the situation of the 'trainee tracer'. The aim is to take into account the experiences of students and the healthcare professionals who work with them, by analysing each phase of the placement process (before, during and after) and exploring the links with training institutes. Currently focused on nursing students, the aim is to extend this approach to the entire paramedical training sector.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.soin.2025.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First Report of 68Ga-FAPI PET/CT Imaging in Fallopian Tube Cancer: Implications for Diagnosis and Staging.
Clin Nucl Med
September 2025
Women Health Program, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), University Medical City, Muscat, Oman.
We report the case of a 47-year-old woman who presented with left inguinal swelling; the biopsy of which showed high-grade serous adenocarcinoma. 68Ga-FAPI PET/CT revealed a tracer-avid lesion in the left adnexal region and an enlarged left inguinal nodal mass (site of biopsy). Multiple focal lesions were also seen at the hepatic dome, along the falciform ligament and at the right lateral abdominal wall, suspicious for peritoneal/metastatic deposits.
View Article and Find Full Text PDFTumor Versus Capillary Telangiectasia in Recurring Glioblastoma.
Clin Nucl Med
September 2025
Departments of Nuclear Medicine.
This image highlights a diagnostic pitfall in a 65-year-old patient with recurrent glioblastoma. 18F-FET-PET revealed 2 hotspots with focally enhanced uptake: local tumor recurrence (TBRmax 2.3) on the left and another lesion in the right anterior cingulate gyrus (TBRmax 1.
View Article and Find Full Text PDF[From 'patient tracer' to 'learner tracer', a new challenge for the AP-HP Nord - Université Paris Cité GHU].
Soins
September 2025
Institut de formation en soins infirmiers Saint-Louis, AP-HP, 12 rue de la Grange aux Belles, 75010 Paris, France.
The Assistance publique - Hôpitaux de Paris. Nord - Université Paris Cité is embarking on a process of continuous evaluation and quality improvement of its placement policy, by transposing the 'patient tracer' method to the situation of the 'trainee tracer'. The aim is to take into account the experiences of students and the healthcare professionals who work with them, by analysing each phase of the placement process (before, during and after) and exploring the links with training institutes.
View Article and Find Full Text PDFFirst clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.
Nuklearmedizin
September 2025
Nuclear Medicine, Ulm University Hospital, Ulm, Germany.
Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.
View Article and Find Full Text PDFNovel Radiofluorinated Nanobody PET Tracer for Preclinical Studies of TIM3 Expression.
Mol Pharm
September 2025
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Departmen
T-cell immunoglobulin and mucin domain-3 (TIM3) is an inhibitory checkpoint glycoprotein expressed on immune cells, particularly tumor-infiltrating lymphocytes (TILs), and plays a critical role in suppressing antitumor immune responses. While dual blockade of TIM3 and programmed cell death protein 1 (PD1) has shown promising results in enhancing immune responses in advanced cancers, the lack of reliable, noninvasive methods for detecting TIM3 expression in tumors remains a major challenge. To address this, we developed and characterized a novel positron emission tomography (PET) tracer, [F]AlF-RESCA-HVCR2N2, based on a TIM3-specific nanobody labeled via [F]AlF radiochemistry.
View Article and Find Full Text PDF